CN103189055A - 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法 - Google Patents

用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法 Download PDF

Info

Publication number
CN103189055A
CN103189055A CN201180051633XA CN201180051633A CN103189055A CN 103189055 A CN103189055 A CN 103189055A CN 201180051633X A CN201180051633X A CN 201180051633XA CN 201180051633 A CN201180051633 A CN 201180051633A CN 103189055 A CN103189055 A CN 103189055A
Authority
CN
China
Prior art keywords
naltrexone
opioid
formulation
oxycodone
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201180051633XA
Other languages
English (en)
Chinese (zh)
Inventor
M·J.·拉姆森
V·戈利
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpharma Pharmaceuticals LLC
Original Assignee
Alpharma Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpharma Pharmaceuticals LLC filed Critical Alpharma Pharmaceuticals LLC
Publication of CN103189055A publication Critical patent/CN103189055A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201180051633XA 2010-10-26 2011-10-25 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法 Pending CN103189055A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40675210P 2010-10-26 2010-10-26
US61/406,752 2010-10-26
PCT/IB2011/054767 WO2012056402A2 (en) 2010-10-26 2011-10-25 Formulations and methods for attenuating respiratory depression induced by opioid overdose

Publications (1)

Publication Number Publication Date
CN103189055A true CN103189055A (zh) 2013-07-03

Family

ID=45470606

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201180051633XA Pending CN103189055A (zh) 2010-10-26 2011-10-25 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法

Country Status (14)

Country Link
US (3) US20140030343A1 (https=)
EP (1) EP2632442A2 (https=)
JP (1) JP2013540807A (https=)
KR (3) KR20130097211A (https=)
CN (1) CN103189055A (https=)
AU (1) AU2011322147A1 (https=)
BR (1) BR112013009267A2 (https=)
CA (1) CA2814230A1 (https=)
IL (1) IL225966A0 (https=)
MX (1) MX2013003832A (https=)
RU (1) RU2541159C2 (https=)
SG (1) SG189234A1 (https=)
WO (1) WO2012056402A2 (https=)
ZA (1) ZA201302363B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US20110104214A1 (en) 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
RU2541159C2 (ru) * 2010-10-26 2015-02-10 АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов
BR112013019431A2 (pt) * 2011-02-02 2020-10-27 Alpharma Pharmaceuticals, Llc composição farmacêutica compreendendo agonista opioide e antagonista sequestrado
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
PT4293009T (pt) 2015-12-22 2025-09-08 Zogenix International Ltd Composições de fenfluramina e métodos de preparação das mesmas
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US10766925B2 (en) * 2016-04-11 2020-09-08 Arizona Board Of Regents On Behalf Of The University Of Arizona Opioid receptor modulators
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
AU2017315273B2 (en) 2016-08-24 2021-04-29 Zogenix International Limited Formulation for inhibiting formation of 5-HT 2B agonists and methods of using same
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
AU2018390826B2 (en) 2017-12-20 2024-09-12 Purdue Pharma L.P. Abuse deterrent morphine sulfate dosage forms
EP3790537A1 (en) 2018-05-11 2021-03-17 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
EP3806835A1 (en) * 2018-06-14 2021-04-21 Zogenix International Limited Compositions and methods for treating respiratory depression with fenfluramine
AU2019384963B2 (en) 2018-11-19 2022-05-26 Zogenix International Limited Methods of treating Rett syndrome using fenfluramine
WO2021072055A1 (en) * 2019-10-11 2021-04-15 Board Of Regents, The University Of Texas System Compositions and methods for preventing, reducing and reversing opioid-induced respiratory depression
US20230063876A1 (en) * 2020-03-02 2023-03-02 Unm Rainforest Innovations Virus-Like Particle Vaccines for Opioid Drugs
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
KR20240101622A (ko) * 2021-11-02 2024-07-02 에날레어 테라퓨틱스 인크. 비아편유사제에 의해 조절되는 호흡 억제의 치료 방법
US12303604B1 (en) 2024-10-16 2025-05-20 Currax Pharmaceuticals Llc Pharmaceutical formulations comprising naltrexone and/or bupropion

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL160222A0 (en) * 2001-08-06 2004-07-25 Euro Celtique Sa Opioid agonist formulations with releasable and sequestered antagonist
WO2005056087A1 (en) * 2003-12-05 2005-06-23 Cardinal Health 303, Inc. Patient-controlled analgesia with patient monitoring system
US8168447B2 (en) 2005-10-07 2012-05-01 University Of Florida Research Foundation, Inc. Multiple component nanoparticles for multiplexed signaling and optical encoding
US20080233156A1 (en) * 2006-10-11 2008-09-25 Alpharma, Inc. Pharmaceutical compositions
EP2197427A2 (en) * 2007-09-04 2010-06-23 Alpharma, Inc. A multilayer pharmaceutical composition comprising an antagonist in a first layer and an agonist in a second layer
CA2709905A1 (en) * 2007-12-17 2009-06-25 Alfred Liang Abuse-resistant oxycodone composition
IT1391530B1 (it) 2008-07-31 2012-01-11 Cyanagen S R L Particelle attive per applicazioni bio-analitiche e metodi per la loro preparazione
CN102231991A (zh) 2008-07-31 2011-11-02 生物工程大学精神物质实验室 应用于生物分析的活性粒子及其制备方法
RU2541159C2 (ru) * 2010-10-26 2015-02-10 АЛФАРМА ФАРМАСЬЮТИКЭЛЗ, ЭлЭлСи Композиции и способы для смягчения дыхательной недостаточности, вызванной передозировкой опиоидов

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100152221A1 (en) * 2007-12-17 2010-06-17 Alpharma Pharmaceuticals, Llc Pharmaceutical composition

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WILLIAM T.DENMAN ETAL: "A Randomized Double-Blind Study of the Effects of Oral Naltrexone on Respiratory Drive Induced by 15-25mg of Immediate-Release Oral Hydrocodone", 《ANESTHESIOLOGY》 *

Also Published As

Publication number Publication date
JP2013540807A (ja) 2013-11-07
AU2011322147A1 (en) 2013-04-18
SG189234A1 (en) 2013-05-31
WO2012056402A2 (en) 2012-05-03
KR20160017668A (ko) 2016-02-16
US20170367987A1 (en) 2017-12-28
BR112013009267A2 (pt) 2016-07-26
MX2013003832A (es) 2013-10-01
RU2541159C2 (ru) 2015-02-10
WO2012056402A3 (en) 2012-10-04
EP2632442A2 (en) 2013-09-04
KR20170102571A (ko) 2017-09-11
US20140030343A1 (en) 2014-01-30
ZA201302363B (en) 2014-06-25
CA2814230A1 (en) 2012-05-03
IL225966A0 (en) 2013-06-27
US20160045449A1 (en) 2016-02-18
KR20130097211A (ko) 2013-09-02
RU2013117274A (ru) 2014-12-10

Similar Documents

Publication Publication Date Title
CN103189055A (zh) 用于缓解阿片类物质用药过量引起的呼吸抑制的制剂和方法
US7034036B2 (en) Inhibitors of ABC drug transporters at the blood-brain barrier
US8623418B2 (en) Pharmaceutical composition
EP1284736A2 (en) Opioid antagonist compositions and dosage forms
US20130122065A1 (en) Pharmaceutical Composition
US20150104519A1 (en) Pharmaceutical Compositions
AU2001259458A1 (en) Opioid antagonist compositions and dosage forms
AU2018232854B2 (en) Novel dosage form
AU2008338439A1 (en) Pharmaceutical composition
CA3068036A1 (en) Use to buprenorphine in combination with an opioid to treat pain
AU2019201397A1 (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
HK1186970A (en) Formulations and methods for attenuating respiratory depression induced by opioid overdose
CA2427330A1 (en) Inhibitors of abc drug transporters at the blood-brain barrier
AU2014216032B2 (en) Pharmaceutical composition
AU2019202760A1 (en) Pharmaceutical composition
AU2014216026A1 (en) Pharmaceutical composition

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1186970

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20130703

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1186970

Country of ref document: HK